Total t-PA Before, During, and After Placebo or 70 ng/min DDAVP Infusion
n = 7 . | Baseline* . | Infusion . | Postinfusion . | ANOVA . | ||||
---|---|---|---|---|---|---|---|---|
After 2 Min . | After 4 Min . | After 15 Min† . | 2 Min Rest . | 10 Min Rest . | One-Way . | Two-Way Placebo v DDAVP . | ||
Total t-PA | ||||||||
Arterial plasma concentration (ng/mL) | ||||||||
Placebo | 5.58 (0.99) | 6.04 (1.21) | 5.87 (1.23) | 6.12 (1.40) | 5.86 (1.07) | 6.26 (1.18) | NS | P = .053 |
DDAVP | 5.27 (0.95) | 5.42 (0.92) | 5.57 (0.92) | 6.26 (1.04) | 5.93 (0.96) | 6.18 (1.07) | P < .0001 | |
Venous plasma concentration (ng/mL) | ||||||||
Placebo | 6.24 (1.06) | 6.18 (1.17) | 6.39 (1.34) | 6.56 (1.49) | 6.17 (1.17) | 6.53 (1.35) | NS | P < .0001 |
DDAVP | 5.54 (0.94) | 6.31 (0.94) | 7.46 (1.02) | 9.10 (1.23) | 8.40 (1.00) | 8.16 (1.16) | P < .0001 | |
A-V concentration gradient (ng/mL) | ||||||||
Placebo | 0.66 (0.13) | 0.14 (0.06) | 0.52 (0.18) | 0.44 (0.21) | 0.32 (0.26) | 0.27 (0.27) | NS | P < .0001 |
DDAVP | 0.28 (0.08) | 0.89 (0.17) | 1.89 (0.68) | 2.84 (0.84) | 2.47 (0.51) | 1.98 (0.57) | P < .0001 | |
Net release (ng × L−1 × min−1) | ||||||||
Placebo | 11.1 (1.97) | 2.41 (0.92) | 8.54 (2.92) | 8.00 (3.24) | 4.91 (3.89) | 5.11 (4.09) | NS | P < .0001 |
DDAVP | 5.83 (2.63) | 37.1 (11.4) | 82.6 (36.1) | 144 (58.0) | 79.9 (23.8) | 52.6 (16.1) | P < .0001 | |
Active t-PA | ||||||||
Arterial plasma concentration (ng/mL) | ||||||||
Placebo | 1.02 (0.15) | 1.09 (0.15) | 1.14 (0.15) | 0.89 (0.22) | 0.94 (0.20) | 1.00 (0.22) | NS | P < .0001 |
DDAVP | 0.98 (0.12) | 1.08 (0.12) | 1.14 (0.13) | 1.35 (0.17) | 1.34 (0.17) | 1.25 (0.15) | P < .0001 | |
Venous plasma concentration (ng/mL) | ||||||||
Placebo | 1.23 (0.24) | 1.30 (0.20) | 1.29 (0.19) | 1.22 (0.20) | 1.27 (0.18) | 1.28 (0.20) | NS | P < .0001 |
DDAVP | 1.16 (0.16) | 1.71 (0.24) | 2.79 (0.58) | 3.77 (0.71) | 3.50 (0.46) | 2.76 (0.45) | P < .0001 | |
A-V concentration gradient (ng/mL) | ||||||||
Placebo | 0.21 (0.09) | 0.21 (0.06) | 0.15 (0.05) | 0.32 (0.18) | 0.33 (0.16) | 0.28 (0.15) | NS | P < .0001 |
DDAVP | 0.19 (0.05) | 0.64 (0.18) | 1.65 (0.53) | 2.42 (0.63) | 2.15 (0.38) | 1.50 (0.38) | P < .0001 | |
Net release (ng × L−1 × min−1) | ||||||||
Placebo | 3.92 (1.70) | 3.34 (1.06) | 2.60 (0.86) | 4.69 (2.71) | 5.98 (2.46) | 4.33 (2.14) | NS | P < .0001 |
DDAVP | 3.38 (1.18) | 23.6 (9.44) | 73.7 (28.9) | 123 (44.3) | 70.4 (18.3) | 41.6 (12.4) | P < .0001 |
n = 7 . | Baseline* . | Infusion . | Postinfusion . | ANOVA . | ||||
---|---|---|---|---|---|---|---|---|
After 2 Min . | After 4 Min . | After 15 Min† . | 2 Min Rest . | 10 Min Rest . | One-Way . | Two-Way Placebo v DDAVP . | ||
Total t-PA | ||||||||
Arterial plasma concentration (ng/mL) | ||||||||
Placebo | 5.58 (0.99) | 6.04 (1.21) | 5.87 (1.23) | 6.12 (1.40) | 5.86 (1.07) | 6.26 (1.18) | NS | P = .053 |
DDAVP | 5.27 (0.95) | 5.42 (0.92) | 5.57 (0.92) | 6.26 (1.04) | 5.93 (0.96) | 6.18 (1.07) | P < .0001 | |
Venous plasma concentration (ng/mL) | ||||||||
Placebo | 6.24 (1.06) | 6.18 (1.17) | 6.39 (1.34) | 6.56 (1.49) | 6.17 (1.17) | 6.53 (1.35) | NS | P < .0001 |
DDAVP | 5.54 (0.94) | 6.31 (0.94) | 7.46 (1.02) | 9.10 (1.23) | 8.40 (1.00) | 8.16 (1.16) | P < .0001 | |
A-V concentration gradient (ng/mL) | ||||||||
Placebo | 0.66 (0.13) | 0.14 (0.06) | 0.52 (0.18) | 0.44 (0.21) | 0.32 (0.26) | 0.27 (0.27) | NS | P < .0001 |
DDAVP | 0.28 (0.08) | 0.89 (0.17) | 1.89 (0.68) | 2.84 (0.84) | 2.47 (0.51) | 1.98 (0.57) | P < .0001 | |
Net release (ng × L−1 × min−1) | ||||||||
Placebo | 11.1 (1.97) | 2.41 (0.92) | 8.54 (2.92) | 8.00 (3.24) | 4.91 (3.89) | 5.11 (4.09) | NS | P < .0001 |
DDAVP | 5.83 (2.63) | 37.1 (11.4) | 82.6 (36.1) | 144 (58.0) | 79.9 (23.8) | 52.6 (16.1) | P < .0001 | |
Active t-PA | ||||||||
Arterial plasma concentration (ng/mL) | ||||||||
Placebo | 1.02 (0.15) | 1.09 (0.15) | 1.14 (0.15) | 0.89 (0.22) | 0.94 (0.20) | 1.00 (0.22) | NS | P < .0001 |
DDAVP | 0.98 (0.12) | 1.08 (0.12) | 1.14 (0.13) | 1.35 (0.17) | 1.34 (0.17) | 1.25 (0.15) | P < .0001 | |
Venous plasma concentration (ng/mL) | ||||||||
Placebo | 1.23 (0.24) | 1.30 (0.20) | 1.29 (0.19) | 1.22 (0.20) | 1.27 (0.18) | 1.28 (0.20) | NS | P < .0001 |
DDAVP | 1.16 (0.16) | 1.71 (0.24) | 2.79 (0.58) | 3.77 (0.71) | 3.50 (0.46) | 2.76 (0.45) | P < .0001 | |
A-V concentration gradient (ng/mL) | ||||||||
Placebo | 0.21 (0.09) | 0.21 (0.06) | 0.15 (0.05) | 0.32 (0.18) | 0.33 (0.16) | 0.28 (0.15) | NS | P < .0001 |
DDAVP | 0.19 (0.05) | 0.64 (0.18) | 1.65 (0.53) | 2.42 (0.63) | 2.15 (0.38) | 1.50 (0.38) | P < .0001 | |
Net release (ng × L−1 × min−1) | ||||||||
Placebo | 3.92 (1.70) | 3.34 (1.06) | 2.60 (0.86) | 4.69 (2.71) | 5.98 (2.46) | 4.33 (2.14) | NS | P < .0001 |
DDAVP | 3.38 (1.18) | 23.6 (9.44) | 73.7 (28.9) | 123 (44.3) | 70.4 (18.3) | 41.6 (12.4) | P < .0001 |